2026 Nanocap Stocks to Watch: IGC, KNRX, GYGY, ARAY Lead Watchlist Now See More Inside!Dallas TX - Sept. 28, 2026 - From AI data centers and Alzheimer’s research to drug safety testing and humanoid robots, six small-cap companies are approaching developments that could shape their next phase of growth.
VivoSim Labs Inc. (NASDAQ: VIVS) Targets the Multibillion-Dollar Cost of Failed DrugsDallas TX - Sept. 28, 2026 - VivoSim Labs Inc. (
NASDAQ: VIVS) is developing human-relevant testing technologies designed to identify unsuccessful drug candidates earlier, potentially improving the economics of pharmaceutical development.
VivoSim Labs Inc. (NASDAQ: VIVS) Takes Aim at Pharma’s 92% Drug-Failure ProblemSept. 18, 2026 - Approximately 92% of drugs entering clinical trials fail before receiving regulatory approval, leaving the pharmaceutical industry with a success rate of only about 8%. VivoSim Labs Inc. (
NASDAQ: VIVS) is developing human-relevant laboratory models designed to identify potential failures earlier before drug developers commit substantial capital to human trials.
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical TrialsSeptember 10, 2026 VivoSim Labs, Inc. (
NASDAQ: VIVS) is targeting one of pharmaceutical development's most expensive challenges: identifying drug toxicity before a candidate reaches human clinical trials. Using its NAMkind™ 3D human liver and intestinal models combined with AI-powered predictive toxicology, VivoSim is developing tools designed to help pharmaceutical companies determine which drug candidates should advance, be modified or be discontinued earlier .
VivoSim Labs (NASDAQ: VIVS): 10,000 Compounds to 1 Drug with AI-Powered 3D Human ToxicologyAugust 26, 2026 — Drug discovery can begin with 5,000 to 10,000 compounds, narrow to approximately 250 entering preclinical development , around five reaching clinical trials and ultimately produce just one approved medicine —highlighting why identifying weak drug candidates earlier can be critical to pharmaceutical R&D.
Nasdaq 30’s VIVS, IGC, RIME, AIXI Stocks NowAugust 26, 2026 — Investor attention is building around several lower-priced small-cap stocks trading near the $0.30 range, including VivoSim Labs, Inc. (
NASDAQ: VIVS), IGC Pharma, Inc. (
NYSE: IGC), Algorhythm Holdings, Inc. (
NASDAQ: RIME) and Xiao-I Corporation (
NASDAQ: AIXI), as company-specific catalysts across AI, biotechnology, drug development and logistics technology drive trading interest.VivoSim Labs (
NASDAQ: VIVS) — AI Drug Toxicity and FDA NAM Momentum
VivoSim Labs (NASDAQ: VIVS) Research Report Highlights AI-Powered Drug Toxicity Platform, FDA NAM MomentumAugust 25, 2026 — VivoSim Labs, Inc. (
NASDAQ: VIVS) is drawing investor attention following an initiation-of-coverage research report highlighting the company's NAMkind™ 3D human tissue models, AI-powered toxicology analytics, early commercial traction and potential opportunity from accelerating adoption of New Approach Methodologies (NAMs).
VivoSim Labs (NASDAQ: VIVS) Among IGC, OSRH, IVF as FDA-Backed Human-Based Testing Gains MomentumAugust 17, 2026 — VivoSim Labs, Inc. (
NASDAQ: VIVS) is gaining investor attention as its 3D human tissue models, artificial intelligence and New Approach Methodologies (NAMs) target one of pharmaceutical development’s biggest challenges: identifying drug toxicity before costly clinical trials.
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built ForNews Provided by USA News Group on behalf of Conexeu Sciences Inc.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
As Medicare’s New GLP-1 Coverage Begins, Ozari Health Publishes 2026 Guide Comparing Every Way to Get Semaglutide and Tirzepatide – From $50 Copays to $86 Cash-Pay OptionsNew York, NY - July 15, 2026 - The GLP-1 access landscape is changing faster in 2026 than at any point since these medications reached the market. Medicare's bridge payment demonstration — offering eligible beneficiaries GLP-1 medications at $50 monthly copays — begins this month. Branded Ozempic, Wegovy, Mounjaro, and Zepbound are now priced at $245 per month through federal pricing agreements announced in late 2025. Oral GLP-1options, including the Wegovy pill and newly approved orforglipron, have expanded the market beyond injections entirely.
Dr. Danielle Carrera’s Beyond Better, Thrive Debuts as Amazon #1 New Release and Top 5 BestsellerTampa, FL, USA - July 3, 2026 - Dr. Danielle M. Carrera, DNP, AAPRN-BC — nationally recognized expert in metabolic health, GLP-1 therapeutics, peptide medicine, and regenerative wellness; Founder & Clinical Director of Carrera Telehealth & Wellness; Co-Founder & CEO of Above Genetics; and Founder of the Bridge2Better Foundation — announces the worldwide release of her new book, Beyond Better: Thrive. More than a wellness book, it is a call to personal leadership, inviting readers to elevate their biology, their mindset, and their future through intentional, science-driven self-authority.
WSTPR Catalyst Watch: Abu Dhabi Regulatory Clearance Adds Momentum to NeOnc's Global Neuro-Oncology StrategyHouston, Texas--(Newsfile Corp. - June 22, 2026) - NeOnc Technologies Holdings (
NASDAQ: NTHI) recently achieved what many biotechnology companies spend...
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease InnovationSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease InnovationRecent Industry Activity Reinforces the Need for Manufacturing Resilience, Diversified Vaccine Supply, and Health Security Amid an Evolving Global Biothreat Landscape
Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness MarketsAnalysts project billions in future market value as biotech innovation and consumer demand continue driving the next wave of health performance products
Peptide Wellness Market Could Near $300 Billion as Consumer Demand AcceleratesNext-generation wellness platforms targeting longevity, metabolism, and performance continue gaining momentum in one of healthcare’s fastest-growing sectors
